Literature DB >> 12213713

Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice.

Melanie A Simpson1, Christopher M Wilson, James B McCarthy.   

Abstract

Hyaluronan (HA), a secreted glycosaminoglycan component of extracellular matrices, is critical for cellular proliferation and motility during development. However, elevated circulating and cell-associated levels correlate with various types of cancer, including prostate. We have previously shown that aggressive PC3M-LN4 prostate tumor cells synthesize excessive HA relative to less aggressive cells, and express correspondingly higher levels of the HA biosynthetic enzymes HAS2 and HAS3. Inhibition of these enzymes by stable transfection of PC3M-LN4 cells with anti-sense HAS2 or HAS3 expression constructs diminishes HA synthesis and surface retention. In this report, we used these HA-deficient cell lines to examine the role of HA in tumorigenicity. Subcutaneous injection of SCID mice with hyaluronan synthase (HAS) antisense-transfected cells produced tumors threefold to fourfold smaller than control transfectants. Tumors from HAS antisense transfectants were histologically HA-deficient relative to controls. HA deficiency corresponded to threefold reduced cell numbers per tumor, but comparable numbers of apoptotic and proliferative cells. Percentages of apoptotic cells in cultured transfectants were identical to those of control cells, but antisense inhibition of HA synthesis effected slower growth rate of cells in culture. Quantification of blood vessel density within tumor sections revealed 70 to 80% diminished vascularity of HAS antisense tumors. Collectively, the results suggest HAS overexpression by prostate tumor cells may facilitate their growth and proliferation in a complex environment by enhancing intrinsic cell growth rates and promoting angiogenesis. Furthermore, this is the first report of a role for inhibition of HA synthesis in reducing tumor growth kinetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213713      PMCID: PMC1867271          DOI: 10.1016/S0002-9440(10)64245-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44.

Authors:  J Brinck; P Heldin
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

2.  Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties.

Authors:  N Itano; T Sawai; M Yoshida; P Lenas; Y Yamada; M Imagawa; T Shinomura; M Hamaguchi; Y Yoshida; Y Ohnuki; S Miyauchi; A P Spicer; J A McDonald; K Kimata
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

3.  Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme.

Authors:  T D Camenisch; A P Spicer; T Brehm-Gibson; J Biesterfeldt; M L Augustine; A Calabro; S Kubalak; S E Klewer; J A McDonald
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer.

Authors:  M A Anttila; R H Tammi; M I Tammi; K J Syrjänen; S V Saarikoski; V M Kosma
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

5.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

6.  Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density.

Authors:  R Wild; S Ramakrishnan; J Sedgewick; A W Griffioen
Journal:  Microvasc Res       Date:  2000-05       Impact factor: 3.514

7.  Expression of human hyaluronan synthases in response to external stimuli.

Authors:  A Jacobson; J Brinck; M J Briskin; A P Spicer; P Heldin
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

8.  Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival.

Authors:  P Auvinen; R Tammi; J Parkkinen; M Tammi; U Agren; R Johansson; P Hirvikoski; M Eskelinen; V M Kosma
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

9.  Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells.

Authors:  N Itano; T Sawai; O Miyaishi; K Kimata
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

10.  Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro.

Authors:  S Yung; G J Thomas; M Davies
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

View more
  48 in total

Review 1.  Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

Authors:  Ki Young Choi; Gurusamy Saravanakumar; Jae Hyung Park; Kinam Park
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-20       Impact factor: 5.268

2.  Hyaluronan and tumor growth.

Authors:  Bryan P Toole; Vincent C Hascall
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

3.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

4.  Caution should be used in long-term treatment with oral compounds of hyaluronic acid in patients with a history of cancer.

Authors:  Procopio Simone; Migliore Alberto
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

5.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Authors:  Vinata B Lokeshwar; Luis E Lopez; Daniel Munoz; Andrew Chi; Samir P Shirodkar; Soum D Lokeshwar; Diogo O Escudero; Neetika Dhir; Norman Altman
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 6.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

7.  Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice.

Authors:  Melanie A Simpson
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

8.  Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

9.  Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.

Authors:  Alamelu G Bharadwaj; Joy L Kovar; Eileen Loughman; Christian Elowsky; Gregory G Oakley; Melanie A Simpson
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

10.  Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer.

Authors:  Geraldine Chow; Jordi Tauler; James L Mulshine
Journal:  J Biomed Biotechnol       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.